Angiotensin II Signalling in Bartter’s and Gitelman’s Syndromes

A Negative Human Model of Hypertension
  • Lorenzo A. Calò
  • Achille C. Pessina
  • Andrea Semplicini
Review Article


In extensive studies of patients with Bartter’s and Gitelman’s syndromes, we have shown biochemical abnormalities in angiotensin II (Ang II) short- and long-term cell signalling, which depict a mirror image of those found in hypertension. The information obtained from the study of this human model of altered vascular tone regulation shows that it can be used to gather more general data and/or confirm mechanistic details of the cellular and biochemical events involved in the pathophysiology of vascular tone control, and to shed light on the multiplicity of the Ang II signalling-related mechanisms responsible for the pathophysiology of hypertension and its long-term complications, such as cardiovascular remodelling and atherogenesis.


  1. 1.
    Touyz RM. Molecular and cellular mechanisms regulating vascular function and structure: implications in the pathogenesis of hypertension. Can J Cardiol 2000; 16: 1137–46PubMedGoogle Scholar
  2. 2.
    Johns DG, Dorrance AM, Leite R, et al. Novel signaling pathways contributing to vascular changes in hypertension. J Biomed Sci 2000; 7: 431–43PubMedCrossRefGoogle Scholar
  3. 3.
    Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 2002; 4: 160–6PubMedCrossRefGoogle Scholar
  4. 4.
    Touyz RM. Role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003; 5: 155–64PubMedCrossRefGoogle Scholar
  5. 5.
    Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047–52PubMedCrossRefGoogle Scholar
  6. 6.
    Griendling KK, Soresen D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494–501PubMedCrossRefGoogle Scholar
  7. 7.
    Nath KA, Grande J, Croatt A, et al. Redox regulation of renal DNA synthesis, transforming growth factor-beta-1 and collagen gene expression. Kidney Int 1998; 53: 367–81PubMedCrossRefGoogle Scholar
  8. 8.
    Abe J, Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardio Med 1998; 8: 59–64CrossRefGoogle Scholar
  9. 9.
    Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517–54PubMedCrossRefGoogle Scholar
  10. 10.
    Immenschuh S, Ramadori G. Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol 2000; 60: 1121–8PubMedCrossRefGoogle Scholar
  11. 11.
    Calò L, Davis PA, Semplicini A. Regulation of vascular tone in Bartter’s and Gitelman’s syndromes. Crit Rev Clin Lab Sci 2000; 37: 503–23PubMedCrossRefGoogle Scholar
  12. 12.
    Naesens M, Steels P, Verberckmoes R, et al. Bartter’s and Gitelman’s syndromes: from gene to clinic. Nephron Physiol 2004; 96: 65–78CrossRefGoogle Scholar
  13. 13.
    Calò L, Davis PA, Semplicini A. Bartter’s/Gitelman’s syndrome: a model for the relationships between hypertension, angiotensin II, oxidative stress and remodeling. Clin Nephrol 2003; 59: 393–4PubMedGoogle Scholar
  14. 14.
    Calò LA, Pagnin E, Davis PA, et al. Oxidative stress related factors in Bartter’s and Gitelman’s syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18: 1518–25PubMedCrossRefGoogle Scholar
  15. 15.
    Pagnin E, Davis PA, Sartori M, et al. Rho kinase and PAI-1 in Bartter’s/Gitelman’s syndromes: relationship to angiotensin II signaling. J Hypertens 2004; 22: 1963–9PubMedCrossRefGoogle Scholar
  16. 16.
    Calò LA, Pagnin E, Davis PA, et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter’s/Gitelman’s syndrome: a role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89: 4153–7PubMedCrossRefGoogle Scholar
  17. 17.
    Calò L, Ceolotto G, Milani M, et al. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001; 60: 882–9PubMedCrossRefGoogle Scholar
  18. 18.
    Calò L, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq protein in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. Kidney Int 2002; 61: 353–4PubMedCrossRefGoogle Scholar
  19. 19.
    Calò L, D’Angelo A, Cantaro S, et al. Intracellular calcium signalling and vascular reactivity in Bartter’s syndrome. Nephron 1996; 72: 570–3PubMedCrossRefGoogle Scholar
  20. 20.
    Di Virgilio F, Calò L, Cantaro S, et al. Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter’s syndrome. Clin Sci 1987; 72: 483–8PubMedGoogle Scholar
  21. 21.
    Calò L, Davis PA, Milani M, et al. Increased endothelial nitric oxide synthase mRNA level in Bartter’s and Gitelman’s syndrome: relationship to vascular reactivity. Clin Nephrol 1999; 51: 12–7PubMedGoogle Scholar
  22. 22.
    Calò L, D’Angelo A, Cantaro S, et al. Increased urinary NO2-/NO3- and cyclic GMP levels in patients with Bartter’s syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27: 874–9CrossRefGoogle Scholar
  23. 23.
    Calò L, Cantaro S, Calabro A, et al. Endothelium-derived vasoactive substances in Bartter’s syndrome. Angiology 1995; 46: 905–13PubMedCrossRefGoogle Scholar
  24. 24.
    Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–12PubMedCrossRefGoogle Scholar
  25. 25.
    Calò L, Sartore G, Bassi A, et al. Reduced susceptibility of low-density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter’s and Gitelman’s syndrome). J Hypertens 1998; 16: 1001–8PubMedCrossRefGoogle Scholar
  26. 26.
    Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361: 315–25PubMedCrossRefGoogle Scholar
  27. 27.
    Davis MJ, Hill MH. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999; 70: 387–423Google Scholar
  28. 28.
    Ciedel CL. Regulation of vascular smooth muscle contraction. Fed Proc 1984; 43: 2390–8Google Scholar
  29. 29.
    Benjamin N, Vallance P. Local control of human peripheral vascular tone: implications for drug therapy. Clin Sci 1991; 80: 183–90PubMedGoogle Scholar
  30. 30.
    Somlyo AP, Somlyo AV. Flash photolysis studies of excitation-contraction coupling, regulation, and contraction in smooth muscle. Annu Rev Physiol 1990; 52: 857–74PubMedCrossRefGoogle Scholar
  31. 31.
    Van Breeman C, Saida K. Cellular mechanisms regulating [Ca2+]i smooth muscle. Annu Rev Physiol 1989; 51: 315–29CrossRefGoogle Scholar
  32. 32.
    Ives HE. Ion transport defects and hypertension: where is the link? Hypertension 1989; 14: 590–7PubMedCrossRefGoogle Scholar
  33. 33.
    Griendling KK, Ushio-Fukai M, Lassegue B, et al. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension 1997; 29: 366–73PubMedCrossRefGoogle Scholar
  34. 34.
    Singer WD, Brown HA, Sternweis PC. Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and D. Annu Rev Biochem 1997; 66: 475–509PubMedCrossRefGoogle Scholar
  35. 35.
    Somlyo AV, Bond M, Somlyo AP, et al. Inositol trisphosphate-induced calcium release and contraction in vascular smooth muscle. Proc Natl Acad Sci U S A 1985; 82: 5231–5PubMedCrossRefGoogle Scholar
  36. 36.
    Galizzi JP, Qar J, Fosset M, et al. Regulation of calcium currents in aortic smooth muscle cells by protein kinase C activators (diacylglycerol and phorbol esters) and by peptides (vasopressin and bombesin) that stimulate phosphoinositide breakdown. J Biol Chem 1987; 262: 6947–50PubMedGoogle Scholar
  37. 37.
    Cole WC, Clement-Chomienne O, Aiello EA. Regulation of 4 aminopyridine-sensitive, delayed rectified K+ channels in vascular smooth muscle by phosphorylation. Biochem Cell Biol 1996; 74: 439–47PubMedCrossRefGoogle Scholar
  38. 38.
    Boulanger MC, Vanhoutte PM. G protein and endothelium-dependent relaxations. J Vasc Res 1997; 34: 175–85PubMedCrossRefGoogle Scholar
  39. 39.
    Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664–6PubMedCrossRefGoogle Scholar
  40. 40.
    Marsden PA, Heng HHQ, Scherer SW, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478–88PubMedGoogle Scholar
  41. 41.
    Clementi E. Role of nitric oxide and its intracellular signalling pathways in the control of Ca2+ homeostasis. Biochem Pharmacol 1998; 55: 713–8PubMedCrossRefGoogle Scholar
  42. 42.
    Davis PA, Calò L. Is atherosclerosis a no NO state? Circulation 1999; 20: 2709–12Google Scholar
  43. 43.
    Calò L, Felice M, Cantaro S, et al. Inhibition of furosemide-sensitive cation transport and activation of sodium-lithium exchange by endogenous circulating factor(s) in Bartter’s and Gitelman’s syndromes. J Hypertens 1997; 15: 1407–13PubMedCrossRefGoogle Scholar
  44. 44.
    Akar F, Skinner E, Klein JD, et al. Vasoconstrictors and nitrovasodilators reciprocally regulate the Na+-K+-Cl- cotransporter in rat aorta. Am J Physiol 1999; 276: C1383–90PubMedGoogle Scholar
  45. 45.
    Sprang SR. G protein mechanisms: insights from structural analysis. Annu Rev Biochem 1997; 66: 639–78PubMedCrossRefGoogle Scholar
  46. 46.
    Ali N, Agrawal DK. Guanine nucleotide binding regulatory proteins: their characteristics and identification. J Pharmacol Toxicol Method 1994; 32: 187–96CrossRefGoogle Scholar
  47. 47.
    Mironneau J, Macrez N. Specificity of Gq and G11 protein signaling in vascular myocites. Trends Cardio Med 1998; 8: 157–62CrossRefGoogle Scholar
  48. 48.
    Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998; 31: 152–61PubMedCrossRefGoogle Scholar
  49. 49.
    Hepler RJ. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci 1999; 20: 376–82PubMedCrossRefGoogle Scholar
  50. 50.
    Zhong H, Neubig RR. Regulator of G protein signalling proteins: novel multifunctional drug targets. J Pharmacol Exp Ther 2001; 297: 837–45PubMedGoogle Scholar
  51. 51.
    Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 2000; 69: 795–827PubMedCrossRefGoogle Scholar
  52. 52.
    Heximer SP, Knutsen RH, Sun X, et al. Hypertension and prolonged vasoconstrictor signalling in RGS2-deficient mice. J Clin Invest 2003; 111: 445–52PubMedGoogle Scholar
  53. 53.
    Yoshida H, Kakuchi J, Yoshikawa N, et al. Angiotensin II type 1 receptor gene abnormality in a patient with Bartter’s syndrome. Kidney Int 1994; 46: 1505–9PubMedCrossRefGoogle Scholar
  54. 54.
    Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562–71PubMedCrossRefGoogle Scholar
  55. 55.
    Fukata Y, Amano M, Kaibuki K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001; 22: 32–9PubMedCrossRefGoogle Scholar
  56. 56.
    Sward K, Mita M, Wilson DP, et al. The role of RhoA and Rho-associated kinase in vascular smooth muscle contraction. Curr Hypertens Rep 2003; 5: 66–72PubMedCrossRefGoogle Scholar
  57. 57.
    Leung T, Manser E, Tan L, et al. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995; 270: 29051–4PubMedCrossRefGoogle Scholar
  58. 58.
    Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996; 15: 2208–16PubMedGoogle Scholar
  59. 59.
    Masumoto A, Hirooka Y, Shimokawa H, et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38: 1307–10PubMedCrossRefGoogle Scholar
  60. 60.
    Takeda K, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK-ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001; 21: 868–73PubMedCrossRefGoogle Scholar
  61. 61.
    Jin L, Ying Z, Webb RC. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol 2004; 287: H1495–500PubMedCrossRefGoogle Scholar
  62. 62.
    Ying Z, Jin L, Dorrance AM, et al. Increased expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens 2004; 17: 981–5PubMedCrossRefGoogle Scholar
  63. 63.
    Gong MC, Gorenne I, Read P, et al. Regulation by GDI of RhoA/Rho-kinase-induced Ca2+ sensitization of smooth muscle myosin II. Am J Physiol Cell Physiol 2001; 28: C257–69Google Scholar
  64. 64.
    Kobayashi N, Nakano S, Mita S, et al. Involvement of Rho-kinase pathway for Ang II-induced plasminogen activator inhibitor gene expression and cardiovascular remodelling in hypertensive rats. J Pharmacol Exp Ther 2002; 301: 459–66PubMedCrossRefGoogle Scholar
  65. 65.
    Jarad G, Simske JS, Sedor JR, et al. Nucleic acid-based techniques for post-transcriptional regulation of molecular targets. Curr Opin Nephrol Hypertens 2003; 12(4): 415–21PubMedCrossRefGoogle Scholar
  66. 66.
    Erne P, Bolli P, Burgisser E, et al. Correlation of platelet calcium with blood pressure: effect of antihypertensive therapy. N Engl J Med 1984; 310: 1084–8PubMedCrossRefGoogle Scholar
  67. 67.
    Sharma RV, Bhalla RC. Calcium and abnormal reactivity of vascular smooth muscle in hypertension. Cell Calcium 1988; 9: 267–74PubMedCrossRefGoogle Scholar
  68. 68.
    Suzuki H, Ikenaga H, Hishikawa K, et al. Increases in NO2-/NO3- excretion in the urine as an indicator of the release of endothelium-derived relaxing factor during elevation of blood pressure. Clin Sci 1992; 82: 631–4PubMedGoogle Scholar
  69. 69.
    Panza JA, Quyyumi AA, Brush Jr JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22–7PubMedCrossRefGoogle Scholar
  70. 70.
    Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997; 30(3 Pt 1): 307–13PubMedCrossRefGoogle Scholar
  71. 71.
    Keys JR, Greene EA, Koch WJ, et al. Gq-coupled receptor agonists mediate cardiac hypertrophy via the vasculature. Hypertension 2002; 40: 660–6PubMedCrossRefGoogle Scholar
  72. 72.
    Tang M, Wang G, Lu P, et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003; 9: 1506–12PubMedCrossRefGoogle Scholar
  73. 73.
    Fukui T, Ishizaka N, Rajagopalan S, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45–51PubMedCrossRefGoogle Scholar
  74. 74.
    Fortuño A, Olivan S, Beloqui O, et al. Association of increased phagocytic NADPH oxidasedependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004; 22: 2169–75PubMedCrossRefGoogle Scholar
  75. 75.
    Porreca E, Di Febbo C, Mincione G, et al. Increased transforming growth factor-production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997; 30: 134–9PubMedCrossRefGoogle Scholar
  76. 76.
    Suthanthiran M, Li B, Song JO, et al. Transforming growth factor-1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 2000; 97: 3479–84PubMedGoogle Scholar
  77. 77.
    Laviades C, Varo N, Diez J. Transforming growth factor- in hypertensives with cardiorenal damage. Hypertension 2000; 36: 517–22PubMedCrossRefGoogle Scholar
  78. 78.
    Ndisang JF, Zhao W, Wang R. Selective regulation of blood pressure by heme oxygenase-1 in hypertension. Hypertension 2002; 40: 315–21PubMedCrossRefGoogle Scholar
  79. 79.
    Durante W. Heme oxygenase-1 in growth control and its clinical application to vascular disease. J Cell Physiol 2003; 195: 373–82PubMedCrossRefGoogle Scholar
  80. 80.
    Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Kho-associated protein kinase in hypertension. Nature 1997; 389: 990–4PubMedCrossRefGoogle Scholar
  81. 81.
    Wolfrum S, Dendorfer A, Rikitake Y, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3 kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24: 1842–7PubMedCrossRefGoogle Scholar
  82. 82.
    Kaikita K, Fogo AB, Ma L, et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104: 839–44PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Lorenzo A. Calò
    • 1
  • Achille C. Pessina
    • 1
  • Andrea Semplicini
    • 1
  1. 1.Department of Clinical and Experimental Medicine, Clinica Medica 4University of PadovaPadovaItaly

Personalised recommendations